AstraZeneca the 'top pick' among European pharmas - broker

Citi rates AstraZeneca PLC a buy and names it its 'top pick' in European pharma, forecasting mid-term sales and EPS as the fastest in the sector with revenue of $82.0bn for 2030 (above an $80.0bn target) and margins in the mid-30% range. The bank's risk-adjusted pipeline is equivalent to 86% of 2024 revenue—more than offsetting a projected 36% revenue loss to patent expiry by 2034—and highlights Phase III readouts in 2026 supporting >$30bn peak sales plus a potential $6bn contribution from baxdrostat. Citi sets a £170 price target vs a current ~£137.84, signalling meaningful upside, while also initiating GSK with a Neutral and £19 target amid concerns around a £7bn HIV portfolio facing LOE from 2026 and flat EPS beyond 2027.

Analysis

Market structure: Citi’s call makes AZN a clear winner (implied upside ~23% to £170 from ~£138) with pockets of European pharma (GSK) as relative losers where patent attrition and flat EPS are highlighted. Expect AZN to gain pricing power and share in hypertension/oncology segments if Phase III/launch execution is clean; generics/HIV players and incumbent GSK face margin pressure. Cross-asset: AZN upside should compress its CDS spreads and could mildly support GBP vs USD on portfolio flows; equity implied vol for AZN will likely decline post-coverage, while bond spreads of weaker peers could widen.

Risk assessment: Tail risks include Phase III failure in 2026 (probability-weighted impact >$30bn peak sales), regulatory rejection of baxdrostat, unexpected manufacturing or launch delays, and faster-than-expected generic erosion pre-2034. Immediate (days–weeks): note-driven re-rating and vol compression; short-term (months): data readouts and launches; long-term (years): patent cliff dynamics to 2034. Hidden dependencies: forecasts assume US pricing/reimbursement and successful commercialization partnerships; any US payer pushback reduces upside materially.

Trade implications: Direct: establish a 2–4% long position in AZN ahead of 2026 Phase III readouts, target £170, stop-loss £125 (≈10% haircut). Pair trade: long AZN / short GSK equal notional to isolate stock-specific execution (reduce market beta). Options: buy 12–18m AZN call spreads (e.g., buy £150, sell £210) to cap capital while capturing upside; consider buying GSK protective puts if short.

Contrarian angles: Consensus may underweight execution risk—Citi’s pipeline valuation (86% of 2024 revenue) is optimistic if launches underperform; conversely GSK may be oversold given improved dividends and balance sheet — a tactical small long (1–2%) if HIV revenue replacement plans clarify. Historical parallel: large-cap pharma reratings post-positive Phase III are durable only with clean US launches; an approval without access would leave upside capped. Monitor upcoming 2026 trial calendar and payer guidance as primary reversal catalysts.

Key Decisions for Investors

• Establish a 2–4% long position in AstraZeneca (AZN) at market (~£137–£145) ahead of 2026 Phase III readouts; target exit at £170 (≈23% upside) or cut to £125 (≈10% downside).
• Implement a pair trade: go long AZN and short GSK (equal notional) to express a stock-specific view while neutralizing broader pharma beta; size combined position at 2–3% net exposure.
• Buy 12–18 month AZN call spreads (example: buy £150, sell £210) sized to limit capital at risk to ~1% of portfolio—captures upside to Citi’s target with defined loss.
• Reduce standalone exposure to mid/late-cycle European pharma names lacking near-term catalysts by 2–3% and reallocate into large-cap, pipeline-driven names (AZN) until 2026 readout cadence is clearer.
• Monitor three specific catalysts over next 9–18 months before scaling: (1) 2026 Phase III readout dates and endpoints for key assets supporting >$30bn peak sales, (2) regulatory filings/approvals for baxdrostat and timing of US payer decisions, (3) GSK HIV exclusivity timeline and announced revenue-replacement deals—act within 7 days of material updates.